Bill > HB1717

This bill modifies provisions related to alternative therapies and treatments, specifically focusing on psilocybin and investigational drugs. For psilocybin, it creates protections from state and local law violations for veterans and first responders aged 21 and older who are suffering from posttraumatic stress disorder (PTSD), major depressive disorder, substance use disorder, or require end-of-life care, provided they are enrolled in a study, have physician documentation of their condition, inform the department of mental health, and use psilocybin under the supervision of a qualified facilitator with specific training. The bill also allows licensed laboratories to test psilocybin for these individuals and allocates funds for research into psilocybin's efficacy for these conditions, with the department of mental health required to report on its implementation and outcomes while maintaining confidentiality and protecting involved parties from liability except in cases of gross negligence or willful misconduct. Additionally, the bill expands access to investigational drugs, biological products, or devices for eligible patients with terminal, life-threatening, or severely debilitating conditions, removing the exclusion of Schedule I controlled substances and clarifying that manufacturers can charge for costs associated with these treatments, while also protecting physicians from disciplinary action for recommending them. Finally, it mandates a study on the efficacy of alternative medicine and therapies, including psilocybin, for veterans with PTSD, major depressive disorder, substance use disorders, or requiring end-of-life care, with reporting requirements and protections for those involved.

Government Affairs

https://house.mo.gov/Bill.aspx?bill=HB1717&year=2026&code=R